
price data provid thomson reuter
number may add due round
remain under-perform rate rais target pegasu data
report price share secondari offer shoe
share time rais consist prior assumpt
howev magnitud dollar size/shar count larger previous
incorpor estim coincid offer manag also
pre-announc cash project pro forma cash extend
runway regulatori discuss continu think
pnh market entri would like fall make pivot
ga data readout import incorpor rais
adjust expens trajectori target increas await
detail data get better understand may fit pnh market
remain under-perform rate
price offer propos offer consist prior
expect term time issu share deal
larger previous model anticip rais
gross proce estim net proce rais
continu anticip separ mileston payment sfj
combin proce manag expect cash/equival
balanc link manag project current cash
runway extend
execut name game cash runway extend
like preced potenti approv pnh manag plan
meet regul get clariti potenti regulatori packag
manag also anticip pivot geograph atrophi ga data
assum enrol complet thu although rais
provid much-need capit import time still see potenti need
extend runway current setup leav littl room delay
model updat increas expens trajectori incorpor rais
make multipl updat model first consist manag pre-
announc cash/equival link cash runway
increas sg expens estim
beyond better tie guidanc addit shift
pnh launch one quarter believ earliest potenti launch
like commenc final introduc new estim
incorpor net cash valuat lower discount rate
previous target move previous
remain under-perform rate share await detail data
eha meet better understand drug may fit landscap
well potenti read-through indic
wedbush secur seek busi compani cover
research report thu investor awar firm may
conflict interest could affect object report investor
consid report singl factor make invest decis
pleas see page report analyst certif import
wedbush view remain under-perform rate rais target pegasu data
report price share secondari offer shoe share
time rais consist prior assumpt howev magnitud dollar
size/shar count larger previous incorpor estim coincid
offer manag also pre-announc cash project pro forma
cash extend runway regulatori discuss continu think
pnh market entri would like fall make pivot ga data readout
import incorpor rais adjust expens
trajectori target increas await detail data get better
understand may fit pnh market remain under-perform rate
model updat make multipl updat model first consist
manag pre-announc cash/equival cash runway mid-
increas sg expens estim beyond better
tie guidanc tabl illustr chang estim
addit shift pnh launch one quarter believ earliest
potenti launch like commenc howev remain trajectori continu
unchang prior estim assum roughli exist soliris/ultomiri
pnh market would elig candid final introduc new estim
valuat methodolog continu incorpor sum-of-part dcf analysi thu net
chang plu incorpor pro forma net cash valuat lower
discount rate previous move target previous
reduct discount rate reflect complet first pivot program see figur
continu leav addit indic potenti upsid await addit data
point inform potenti success area
remain under-perform rate share await detail data eha meet
better understand drug may fit landscap well potenti read-
indic
incom statement
good sold
loss extinguish debt
loss remeasur dev deriv liabil
loss remeasur fair valu warrant
 expens revenu
sg expens revenu
price target deriv sum-of-part dcf model examin potenti cash flow deriv discount
back per year
risk attain price rate
clinic data emerg clinic studi significantli impact share either posit neg direct
regulatori apelli may employ acceler strategi gain approv regul may requir addit data could alter
requir approv necessit addit longer studi failur gain product label lack certain featur could
limit apelli abil gain traction market
apelli requir addit fund fulli develop share may neg impact compani abil
access capit market
commerci failur execut commerci inabl meet/exce expect impact share
competit updat competitor may posit neg impact share relev competitor includ compani
alexion roch competitor like emerg time
generic/biosimilar entri new gener biosimilar agent may put pressur apelli exist market product
limit compani abil realiz increas price
singl product risk major apelli develop effort relat drug deem unsaf unabl
advanc share like neg impact
laura chico certifi view express report accur reflect person opinion
directli indirectli receiv compens payment connect specif recommend view contain
report
outperform expect total return stock outperform rel median total return analyst analyst
team coverag univers next month
neutral expect total return stock perform in-lin median total return analyst analyst team
coverag univers next month
under-perform expect total return stock under-perform rel median total return analyst
analyst team coverag univers next month
invest rate base expect perform stock base anticip total return price target rel
stock analyst coverag univers analyst team coverag
januari
januari
distribut rate requir finra rule howev ws stock rate outperform neutral under-perform
close conform buy hold sell respect pleas note howev definit ws stock rate
rel basi
analyst respons prepar research report receiv compens base specif invest bank activ
analyst receiv compens base upon variou factor includ ws total revenu portion gener
ws invest bank activ
